ClinicalTrials.gg
CompletedNCT00394771Updated Jul 26, 2013Results posted

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

A Phase 2 interventional study of DR-1031 and Seasonale® in Breakthrough Bleeding, sponsored by Duramed Research. Completed at 50 sites in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-26.

Sponsored by Duramed Research (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
567
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Metrorrhagia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Metrorrhagia · United States.

Enrollment
Largest of 40
567 · median 60
Started
2006
with 1 other
Phase 2
Only one
of the 43
Registered
4th of 43
by date

Among the 43 studies in Metrorrhagia with a site in United States, this one has the largest enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2006, is the only one in phase 2, and was the 4th registered.

Metrorrhagia

153 studies on the registry are indexed under Metrorrhagia; 35 are open to participants now.

Browse Metrorrhagia studies →

Open to participants now

8 of the 43 studies in Metrorrhagia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Metrorrhagia studies recruiting now, 9 (45%) set no upper age limit and 11 (55%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Metrorrhagia with a site in United States, or all of them as a file.
02

Study summary

This is a 4-arm study to evaluate and compare bleeding patterns between three different doses of DR-1031 oral contraceptive with Seasonale oral contraceptive. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary

Read the detailed description

This Phase 2, prospective, multicenter, double-blinded, randomized study is designed to evaluate and compare bleeding patterns in women using one of three different doses of DR-1031 oral contraceptive with Seasonale oral contraceptive.

Patients who meet all study entrance criteria will be randomly assigned to one of four treatment groups,

The overall study duration will be approximately 9 months; this will include a screening period of approximately 4 weeks, a run-in period of 4 weeks, a treatment period of approximately 6 months (two,91-day cycles) and a final study visit occurring 14-21 days after completion of study drug.

03

Conditions studied

  • Breakthrough Bleeding

Browse trials for

Keywords

  • oral contraceptives
  • breakthrough bleeding
  • spotting
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal
  • Not pregnant or breastfeeding
  • Agree to use back-up non-hormonal for study period

Exclusion criteria

Exclusion Criteria:

  • Any to the use of oral
  • Pregnancy within the last 3 months
  • Smoking >10 cigarettes per day
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
567 participants (actual)

Study arms

  • Experimental
    Low Dose DR-1031

    42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.

    Drug: DR-1031 · Drug: Portia®

  • Experimental
    Midrange Dose DR-1031

    21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.

    Drug: DR-1031 · Drug: Portia®

  • Experimental
    High Dose DR-1031

    21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.

    Drug: DR-1031 · Drug: Portia®

  • Active comparator
    Seasonale

    84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.

    Drug: Seasonale® · Drug: Portia®

Interventions

  • DrugDR-1031

    Drug pages: Levonorgestrel · Ethinyl Estradiol

    Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.

    Also known as: levonorgestrel/ethinyl estradiol, Quartette®

  • DrugSeasonale®

    84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.

    Also known as: levonorgestrel/ethinyl estradiol

  • DrugPortia®

    Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.

    Also known as: levonorgestrel/ethinyl estradiol

06

What researchers measure

Primary outcomes

  1. Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)

    Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.

    Time frame: Day 1-84

  2. Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)

    Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.

    Time frame: Day 92-176

Secondary outcomes

  1. Days With Bleeding During Active Cycle 1 (Day 1-84)

    Bleeding is defined as a flow heavy enough to require sanitary protection.

    Time frame: Day 1-84

  2. Days With Bleeding During Active Cycle 2 (Day 92-176)

    Bleeding is defined as a flow heavy enough to require sanitary protection.

    Time frame: Day 92-176

  3. Time to First Bleeding Day

    Time to first bleeding day was defined as the time between the start of intervention until the first day when bleeding was heavy enough to require the use of sanitary protection. Data are not summarized due to limitations in the diary data and an inability to accurately determine a participant's first day of bleeding.

    Time frame: Day 1-84

  4. Maximum Bleeding Severity During Active Cycle 1 (Day 1-84)

    Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy. Data was not summarized due to limitations in the diary data, and an inability to accurately determine the maximum bleeding severity. See pre-specified analyses for Number of Moderate to Heavy Bleeding Days.

    Time frame: Day 1-84

  5. Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)

    Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 1.

    Time frame: Day 85-91

  6. Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)

    Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 2.

    Time frame: Day 177-183

  7. Participants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)

    Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.

    Time frame: Day 1-84

  8. Participants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)

    Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.

    Time frame: Day 92-176

  9. Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)

    Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.

    Time frame: Day 85-91

  10. Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)

    Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.

    Time frame: Day 177-183

Other outcomes

  1. Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)

    Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.

    Time frame: Day 1-84

  2. Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)

    Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.

    Time frame: Day 92-176

07

Results

Posted Jun 19, 2013

Participant flow

Participant flow — Overall Study
MilestoneLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Started140136143148
Intent to treat (itt) population110110108120
Completed9910296109
Not completed41344739
Withdrew: Did not meet protocol requirements1020
Withdrew: Protocol violation2497
Withdrew: Withdrawal by subject106812
Withdrew: Adverse event105128
Withdrew: Participant pregnant0122
Withdrew: Lost to follow-up15151310
Withdrew: Other3310

Outcome measures

PrimaryDays With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.

Time frame:
Day 1-84
Reported as:
Median · days
Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)
daysLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)13 (0 to 67)13.5 (0 to 65)15 (0 to 69)15 (0 to 56)
SecondaryDays With Bleeding During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection.

Time frame:
Day 1-84
Reported as:
Median · days
Days With Bleeding During Active Cycle 1 (Day 1-84)
daysLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Days With Bleeding During Active Cycle 1 (Day 1-84)3.5 (0 to 24)2.5 (0 to 49)4 (0 to 47)2 (0 to 24)
SecondaryDays With Bleeding During Active Cycle 2 (Day 92-176)

Bleeding is defined as a flow heavy enough to require sanitary protection.

Time frame:
Day 92-176
Reported as:
Median · days
Days With Bleeding During Active Cycle 2 (Day 92-176)
daysLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Days With Bleeding During Active Cycle 2 (Day 92-176)1 (0 to 24)2 (0 to 49)1 (0 to 27)2 (0 to 23)
SecondaryTime to First Bleeding Day

Time to first bleeding day was defined as the time between the start of intervention until the first day when bleeding was heavy enough to require the use of sanitary protection. Data are not summarized due to limitations in the diary data and an inability to accurately determine a participant's first day of bleeding.

Time frame:
Day 1-84

No measurements were reported for this outcome.

SecondaryMaximum Bleeding Severity During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy. Data was not summarized due to limitations in the diary data, and an inability to accurately determine the maximum bleeding severity. See pre-specified analyses for Number of Moderate to Heavy Bleeding Days.

Time frame:
Day 1-84

No measurements were reported for this outcome.

PrimaryDays With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)

Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.

Time frame:
Day 92-176
Reported as:
Median · days
Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)
daysLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)6 (0 to 74)7 (0 to 70)5 (0 to 74)6 (0 to 55)
SecondaryParticipants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)

Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 1.

Time frame:
Day 85-91
Reported as:
Number · participants
Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)
participantsLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
0 day14282527
1-3 days36172718
4-7 days59635475
SecondaryParticipants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)

Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 2.

Time frame:
Day 177-183
Reported as:
Number · participants
Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)
participantsLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
0 day15202321
1-3 days32322624
4-7 days50444560
SecondaryParticipants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)

Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.

Time frame:
Day 1-84
Reported as:
Number · participants
Participants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)
participantsLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Breast tenderness/pain58575064
Headache83848692
Bloating80767284
Pelvic pain72656167
Anxiety42433459
Depression51403652
Irritability72696678
SecondaryParticipants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)

Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.

Time frame:
Day 92-176
Reported as:
Number · participants
Participants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)
participantsLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Breast tenderness/pain46474444
Headache74727278
Bloating64645770
Pelvic pain58574557
Anxiety40403147
Depression41393044
Irritability55635465
SecondaryParticipants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)

Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.

Time frame:
Day 85-91
Reported as:
Number · participants
Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)
participantsLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Breast tenderness/pain33281733
Headache57505750
Bloating61514662
Pelvic pain50493753
Anxiety26171422
Depression25211723
Irritability44432336
SecondaryParticipants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)

Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.

Time frame:
Day 177-183
Reported as:
Number · participants
Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)
participantsLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Breast tenderness/pain29251525
Headache39423748
Bloating51533860
Pelvic pain52423151
Anxiety21221322
Depression18211517
Irritability39372539
Other pre-specifiedNumber of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.

Time frame:
Day 1-84
Reported as:
Median · days
Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)
daysLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)0 (0 to 12)0 (0 to 19)0 (0 to 16)0 (0 to 21)
Other pre-specifiedNumber of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)

Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.

Time frame:
Day 92-176
Reported as:
Median · days
Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)
daysLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)0 (0 to 11)0 (0 to 13)0 (0 to 8)0 (0 to 7)

Adverse events

Collected over Day 1 up to Day 256 (longest treatment plus 14 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose DR-1031—1/140 (0.7%)61/140 (43.6%)
Midrange Dose DR-1031—2/136 (1.5%)44/136 (32.4%)
High Dose DR-1031—3/143 (2.1%)49/143 (34.3%)
Seasonale—5/148 (3.4%)53/148 (35.8%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1400/1362/1430/148
Road traffic accidentInjury, poisoning and procedural complications0/1400/1360/1432/148
CholecystitisHepatobiliary disorders0/1401/1360/1430/148
PyelonephritisInfections and infestations0/1401/1360/1430/148
Post procedural bile leakInjury, poisoning and procedural complications0/1401/1360/1430/148
HemiparesisNervous system disorders1/1400/1360/1430/148
HypoaesthesiaNervous system disorders1/1400/1360/1430/148
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1400/1361/1430/148
Small intestinal obstructionGastrointestinal disorders0/1400/1360/1431/148
VomitingGastrointestinal disorders0/1400/1360/1431/148
Most frequent other events
Most frequent other events
EventLow Dose DR-1031Midrange Dose DR-1031High Dose DR-1031Seasonale
HeadacheNervous system disorders19/14019/13623/14319/148
NasopharyngitisInfections and infestations15/1407/1368/1438/148
DysmenorrhoeaReproductive system and breast disorders13/1406/1365/1437/148
SinusitisInfections and infestations10/1406/1362/1436/148
Upper respiratory tract infectionInfections and infestations9/1407/1365/1439/148
Weight increasedInvestigations6/1404/1369/1438/148
Urinary tract infectionInfections and infestations8/1401/1365/1432/148
MigraineNervous system disorders2/1407/1361/1432/148
Back painMusculoskeletal and connective tissue disorders7/1407/1365/1436/148

Baseline characteristics

ITT population

Age Continuous
Age Continuous(years)Low Dose DR-1031Midrange Dose DR-1031High Dose DR-1031SeasonaleTotal
Mean30.1 ± 6.8830.5 ± 7.0230.7 ± 7.6130.6 ± 6.9030.5 ± 7.08
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose DR-1031Midrange Dose DR-1031High Dose DR-1031SeasonaleTotal
Female110110108120448
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Low Dose DR-1031Midrange Dose DR-1031High Dose DR-1031SeasonaleTotal
African-American2120181776
Asian14139
Caucasian72686982291
Hispanic1317191665
Other31127
Weight
Weight(lbs)Low Dose DR-1031Midrange Dose DR-1031High Dose DR-1031SeasonaleTotal
Mean156.6 ± 28.84153.6 ± 27.18156.0 ± 30.79151.9 ± 30.03154.4 ± 29.22
Body Mass Index
Body Mass Index(kg/m^2)Low Dose DR-1031Midrange Dose DR-1031High Dose DR-1031SeasonaleTotal
Mean26.6 ± 4.1325.7 ± 4.2426.0 ± 4.5925.5 ± 4.4125.9 ± 4.35
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)Low Dose DR-1031Midrange Dose DR-1031High Dose DR-1031SeasonaleTotal
Mean114.2 ± 10.74114.4 ± 10.34115.6 ± 9.31112.8 ± 10.23114.2 ± 10.19
Diastolic Blood Pressure
Diastolic Blood Pressure(mmHg)Low Dose DR-1031Midrange Dose DR-1031High Dose DR-1031SeasonaleTotal
Mean72.3 ± 8.8572.9 ± 7.4671.8 ± 7.7271.4 ± 8.4472.1 ± 8.14
Heart Rate
Heart Rate(beats/minute)Low Dose DR-1031Midrange Dose DR-1031High Dose DR-1031SeasonaleTotal
Mean73.9 ± 9.8573.7 ± 8.9073.7 ± 9.1771.9 ± 9.0773.3 ± 9.26

2 further baseline measures are reported on the registry.

08

Study locations

50 sites
  • Duramed Investigational Site
    Huntsville, Alabama 35801, United States
  • Duramed Investigational Site
    Tucson, Arizona 85741, United States
  • Duramed Investigational Site
    Little Rock, Arkansas 72205, United States
  • Duramed Investigational Site
    San Diego, California 92108, United States
  • Duramed Investigational Site
    San Francisco, California 94102, United States
  • Duramed Investigational Site
    Santa Ana, California 92705, United States
  • Duramed Investigational Site
    Vista, California 92083, United States
  • Duramed Investigational Site
    Pueblo, Colorado 81001, United States
  • Duramed Investigational Site
    Stratford, Connecticut 06615, United States
  • Duramed Investigational Site
    Deland, Florida 32720, United States
  • Duramed Investigational Site
    Jacksonville, Florida 32207, United States
  • Duramed Investigational Site
    Melbourne, Florida 32935, United States
  • Duramed Investigational Site
    Miami, Florida 33186, United States
  • Duramed Investigational Site
    Tampa, Florida 33607, United States
  • Duramed Investigational Site
    West Palm Beach, Florida 33401, United States
  • Duramed Investigational Site
    West Palm Beach, Florida 33407, United States
  • Duramed Investigational Site
    Alpharetta, Georgia 30005, United States
  • Duramed Investigational Site
    Douglasville, Georgia 30134, United States
  • Duramed Investigational Site
    Savannah, Georgia 31406, United States
  • Duramed Investigational Site
    Boise, Idaho 83712, United States
  • Duramed Investigational Site
    Meridian, Idaho 83642, United States
  • Duramed Investigational Site
    Fort Wayne, Indiana 46825, United States
  • Duramed Investigational Site
    Wichita, Kansas 67205, United States
  • Duramed Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Duramed Investigational Site
    Metairie, Louisiana 70006, United States
  • Duramed Investigational Site
    Shreveport, Louisiana 71106, United States
  • Duramed Investigational Site
    Riverdale, Maryland 20737, United States
  • Duramed Investigational Site
    Kansas City, Missouri 64114, United States
  • Duramed Investigational Site
    Las Vegas, Nevada 89109, United States
  • Duramed Investigational Site
    Las Vegas, Nevada 89128, United States
  • Duramed Investigational Site
    N. Las Vegas, Nevada 89030, United States
  • Duramed Investigational Site
    Lebanon, New Hampshire 03756, United States
  • Duramed Investigational Site
    Cary, North Carolina 27511, United States
  • Duramed Investigational Site
    New Bern, North Carolina 28562, United States
  • Duramed Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Duramed Investigational Site
    Cleveland, Ohio 44122, United States
  • Duramed Investigational Site
    Mayfield Heights, Ohio 44124, United States
  • Duramed Investigational Site
    Eugene, Oregon 97401, United States
  • Duramed Investigational Site
    Medford, Oregon 97504, United States
  • Duramed Investigational Site
    Pittsburgh, Pennsylvania 15206, United States
  • Duramed Investigational Site
    Charleston, South Carolina 29425, United States
  • Duramed Investigational Site
    Columbia, South Carolina 29201, United States
  • Duramed Investigational Site
    Hilton Head Island, South Carolina 29926, United States
  • Duramed Investigational Site
    Jackson, Tennessee 38305, United States
  • Duramed Investigational Site
    Austin, Texas 78737, United States
  • Duramed Investigational Site
    Dallas, Texas 75390, United States
  • Duramed Investigational Site
    Houston, Texas 77024, United States
  • Duramed Investigational Site
    San Antonio, Texas 78229, United States
  • Duramed Investigational Site
    Salt Lake City, Utah 84102, United States
  • Duramed Investigational Site
    Williston, Vermont 05495, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 5 years 3 months after primary completion. A results delay was requested in Jun 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2006
First posted
Nov 1, 2006
Start
Oct 2006
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results delay requested
Jun 8, 2011
Results first posted
Jun 19, 2013
Last update
Jul 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00394771
Lead sponsor
Duramed Research
Responsible party
Sponsor
First posted
Nov 1, 2006
Start date
Oct 2006
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Jun 19, 2013
Last update
Jul 26, 2013

Study contacts

Duramed Medical Monitor
principal investigator · Duramed Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol

Start the discussion